MNKDMANNKIND CORPvs its industry peers
A metric-by-metric comparison of MANNKIND CORP against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MNKDEsta | $1.1B#8 | — | — | 3.3x#4 | 22.2%#3 | -78.7%#11 | 11.1%#3 | — | 2283.8%#1 | — | -33.8%#12 | — |
| HROW | $1.3B#1 | — | 84.4x#12 | 4.7x#5 | 36.4%#1 | 70.6%#3 | 11.2%#2 | -33.8%#8 | 13.2%#3 | 6#1 | -20.2%#10 | — |
| RARE | $1.3B#2 | — | — | 1.9x#2 | 20.2%#4 | -1.1%#4 | -79.5%#5 | — | — | — | -56.3%#13 | — |
| OMER | $1.3B#3 | 10.0x#1 | — | 17.0x#7 | -34.0%#8 | 97.9%#1 | -166.4%#6 | — | -151.8%#6 | — | 328.7%#3 | — |
| AKTS | $1.2B#4 | — | 2.5x#6 | — | — | — | — | 0.0%#2 | — | — | 23319.4%#1 | — |
| OPK | $1.2B#5 | — | 1.0x#1 | 2.0x#3 | -14.9%#7 | -324.0%#14 | -19.3%#4 | -19058.1%#12 | -13.3%#4 | 4#3 | 16.2%#8 | — |
| SPTX | $1.2B#6 | — | 2.8x#7 | — | — | — | — | 0.0%#2 | — | — | — | — |
| ANRO | $1.2B#7 | — | 5.4x#9 | — | — | -2.9%#5 | — | -28.8%#6 | — | — | 664.8%#2 | — |
| MLTX | $1.1B#9 | — | 2.5x#5 | — | — | -91.1%#13 | — | -53.1%#9 | -491.6%#7 | — | -76.6%#14 | — |
| JBIO | $1.1B#10 | — | 2.4x#4 | — | — | -83.0%#12 | — | -29.0%#7 | — | — | 133.9%#4 | — |
| SVRA | $1.1B#11 | — | 7.4x#10 | 4109.2x#9 | — | -23.9%#7 | -48072.8%#9 | -82.7%#10 | -93.6%#5 | — | 41.8%#6 | — |
| OBX | $1.1B#12 | — | — | — | — | -21.1%#6 | — | — | — | — | — | — |
| CRVS | $1.0B#13 | — | 4.6x#8 | — | — | 75.4%#2 | — | -6.8%#4 | — | — | 112.5%#5 | — |
| AMPH | $1.0B#14 | 14.2x#2 | 2.3x#3 | 1.4x#1 | -1.7%#5 | -38.5%#8 | 19.5%#1 | 22.0%#1 | 13.2%#2 | 5#2 | -11.1%#9 | — |
| KURA | $996M#15 | — | 20.6x#11 | 14.8x#6 | 25.2%#2 | -60.2%#9 | -449.9%#7 | -575.4%#11 | — | — | 34.0%#7 | — |
| JANX | $993M#16 | — | 1.1x#2 | 99.3x#8 | -5.6%#6 | -64.7%#10 | -1576.7%#8 | -12.2%#5 | — | — | -30.6%#11 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice